Career history of Feng Tian
Former positions of Feng Tian
| Companies | Position | Start | End |
|---|---|---|---|
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Director/Board Member | 01/07/2018 | 01/11/2020 |
| Chief Executive Officer | 01/07/2018 | 15/08/2022 | |
| Chairman | 01/11/2020 | 15/08/2022 | |
| Chief Tech/Sci/R&D Officer | 01/01/2015 | 01/07/2018 | |
| President | 01/07/2018 | 15/08/2022 | |
| LuxVitae Therapeutics, Inc. | Founder | - | - |
| AMBRX INC | Chief Executive Officer | - | - |
| Chairman | - | - | |
| Chief Tech/Sci/R&D Officer | 17/06/2015 | - | |
| President | - | - |
Training of Feng Tian
| University of Florida | Doctorate Degree |
| Peking University | Undergraduate Degree |
Statistics
International
| United States | 5 |
| China | 2 |
Operational
| Chief Executive Officer | 2 |
| Chairman | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectoral
| Health Technology | 3 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 3 |
|---|---|
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
| LuxVitae Therapeutics, Inc. |
- Stock Market
- Insiders
- Feng Tian
- Experience
